AstraZeneca Urges “Basket” Approach To Rx Pricing Debate
Executive Summary
Average U.S. drug prices across a "basket" of products are not significantly different than other markets, AstraZeneca CEO Tom McKillop maintained during an investor business review in Wilmington, Del. Oct. 2
You may also be interested in...
Rx Pricing Plan Offered By FDA’s McClellan; Industry Must Meet “Challenge”
The pharmaceutical industry must "work harder" to establish equitable pricing models, FDA Commissioner McClellan declared during a Sept. 25 address to the First International Colloquium on Generic Medicine in Cancun, Mexico
Reimportation Likely In 2003, Merck Says, But HHS Certification Should Stay
Merck expects Congress to pass reimportation legislation in 2003 but to retain the requirement that HHS certify the safety of the program before it is implemented
Rx Pricing Debate Must Be Framed As Trade Issue, Pfizer CEO Says
The pharmaceutical industry needs to re-cast the global pricing and reimportation debate as a trade issue, Pfizer CEO Henry McKinnell told the Bear Stearns conference in New York City Sept. 8